Requiring pharmacy compounding of local anesthesia would presumably increase costs and would not necessarily confer any benefit to patient safety.
Atopic dermatitis is not a risk factor for keratoconus: A population-based cohort study
To the Editor: Keratoconus is an eye disorder in which the cornea becomes thin and bulges out in a conical shape. Conflicting results have been reported in the literature regarding whether atopic dermatitis (AD) is associated with keratoconus development. 1, 2 So far, only case series have shown an association between AD and keratoconus. 3 Hence, we investigated the risk of keratoconus in young Korean patients with AD by using the National Health Insurance ServiceeNational Sample Cohort database, which includes a random sample of 1,025,340 Koreans with claims made over a 12-year period (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) ). 4 For analysis 1-a longitudinal cohort analysiswe included 34,375 patients with incident AD (16,159 women [47%]) younger than 20 years who (1) had a disease-free period of at least 2 years before the incident date and (2) had at least 1 more AD-related visit and received 1 of the following drugs within a year of the incident date: oral antihistamines, topical corticosteroids, or topical calcineurin inhibitors. Among these, we defined patients with severe AD (3734 cases, including 1571 in women [42%]) as those receiving systemic drug(s) for AD treatment in accordance with established guidelines within a year of the incident date. 5 We matched 4 controls to each patient with AD by using propensity scores based on age, sex, residential area, and household income; 137,500 controls (11,089 controls for severe cases) were matched for the analysis 1 (Fig 1) . There were no significant differences in the incidence probability of newly diagnosed keratoconus between the AD and control groups (0.01% versus 0.04% at 10 years [P ¼ .16]) (Fig 2) or between the severe AD and control groups (0% versus 0.01% at 10 years [P ¼ .31]). After control for age, sex, residential area, household income, and comorbidities, the adjusted hazard ratio of keratoconus was 0.36 (95% confidence interval, 0.08-1.54; P ¼ .17) in the AD cohort and 1.87 (95% confidence interval, 0.43-8.22; P ¼ .41) in the severe AD cohort relative to the control group.
For analysis 2-a nested case-control study-we included 229 patients with incident keratoconus who were younger than 30 years and 2290 controls matched by using propensity scoring as mentioned earlier. We defined a history of AD as the presence of any AD-related visits within 2 years before the keratoconus incident date and patients with severe AD as those receiving systemic drugs during those 2 years. There was no significant difference between the keratoconus and control groups in terms of the proportion of patients with AD (7.0% versus 6.5% [P ¼ .76]) or severe AD (1.8% versus 1.4% [P ¼ .68]) during the 2 years before the incident date.
We could not define eye rubbing as a control variable in eligible subjects; this is an inherent limitation of studies analyzing claims databases.
In conclusion, our population-based study suggests that AD in young Korean patients is not associated with a risk of keratoconus. However, because of ethnic differences, these findings are not necessarily applicable to other populations. Our results are helpful in that they provide a background for further studies on the association between AD and keratoconus. Conflicts of interest: None disclosed.
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To the Editor: Thalidomide (ie, -N-phthalimido glutarimide) has shown efficacy in treating severe cutaneous lupus erythematosus (CLE). However, its efficacy needs to be balanced against the potential adverse events, including thromboembolic events (TEs), which might be life-threatening. 1 The pooled-rate of TEs has been estimated to be 2% (95% confidence interval [CI] 1%-3%). 1 However, clinical and biologic factors associated with the risk for TEs remain unknown. This multicenter, retrospective observational study included histologically confirmed CLE patients treated with thalidomide in 5 dermatology departments of French university hospitals during 1992-May 2017. We recorded all TEs occurring during thalidomide treatment and assessed the risk for TEs by 100 Atopic dermatitis (AD). Kaplan-Meier plot of incidence probability of keratoconus in patients with AD and control subjects. There was no statistically significant difference in the incidence probability of keratoconus between the AD and control groups (0.01% and 0.04% at 10 years, respectively [P ¼ .16, log-rank test]).
